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Objective: Increased progesterone level during follicular phase seemed to be associated with decreased pregnancy
rate.
Study design and methods: A prospective cohort study, 1.1.2012 - 31.8.13. The Progesterone (P) and
Progesterone/Estrogen (P/E2) level on ovulation induction day were compared between the protocols and the
different gonadotropins used. Roc analysis was calculated to determine the cutoff of P/E2 to predict delivery rates.
P/E2 ratio was calculated as PX1000/e2 level.
Main results: One hundred thirty-nine patients were enrolled to the study. No difference in the P level at hCG
stimulation day between different protocols, however, E2 and P/E2 ratio were significantly lower in the long
protocol compare with antagonist protocol 1757.7 ± 923.2 vs. 1342.9 ± 1223; P = 0.003 and 0.48 ± 0.31 vs. 0.83 ± 0.87;
P = 0.038). The endometrium was significantly thicker in the long group compare with short and antagonist.
Significantly more top-quality embryos (TOP) were achieved in the antagonist group. Comparable results between
the types of gonadotropins used in regards with cycle characteristics and pregnancy and delivery rates. The P/E2
ratio which can predict live birth rate was found to be 0.45, AUC = 0.632, p = 0.02 and 95 % CI 0.525–0.738 and a
significantly higher pregnancy and delivery rates at a P/E2 bellow 0.45.
Conclusion: Endometrial receptivity is determined by the complex interactions of E2 and P.
Keywords: Progesterone, Progesterone/estrogen ratio, Pregnancy rate, Delivery rare, ROC (AUC)Capsule
More Pregnancies and deliveries after IVF cycles were
achieved in women who had lower progesterone to es-
tradiol ratio on day of hCG.Introduction
Progesterone plays an important role during luteal
phase, particularly vital in creating decidualization
changes needed for implantation and progression of
pregnancy. In IVF treatments premature progesterone
elevation occurs between 5 and 30 % of the treatments
despite the use of GnRH analogs [1–3]. The increased* Correspondence: einatshalompaz@gmail.com
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associated with decreased pregnancy rate [4, 5].
The pathophysiology which creates the premature
elevation of progesterone is not clear; some suggested
it follows an increase number of follicles and in the
presence of high estradiol levels [5]. The correlation
between progesterone and estradiol was evaluated in
several studies in different population. Younis et al.
claimed that P/E2 ratio was more accurate to detect
low ovarian reserve and less oocyte were retrieved on
OPU [6]. Other studies showed that elevation in P/E2
ratio revealed higher oocytes collection and didn’t harm
the pregnancy rates in normo-ovulatory patients [1, 7, 8].
To date, the approach to patients with elevated P
levels on the hCG administration day is under a contro-
versy whether embryos should be transfer or not. On
one hand, the raised peripheral concentrations ofrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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fluence the secretory changes of the endometrium, lead-
ing to impaired endometrial receptivity and premature
decidualization [9] and as a consequence a decreased
probability for ongoing pregnancy [1, 2, 4]. On the other
hand the oocyte and embryo quality were not adversely
affected [10, 11].
To the best of our knowledge, no data was published
comparing the difference between treatment protocols
and type of gonadotropins administered during stimula-
tion and progesterone levels progesterone/estradiol ratio
and treatment outcome.
We assumed that the GnRH analog and gonadotropins
used during stimulation may have an influence on proges-
terone level and P/E2 ratio. The primary objective was to
establish a serum P and P/E2 ratio threshold that would
define detrimental levels to cycle outcomes. As a second-
ary objective, we aimed to determine the correlation be-
tween serum P levels and P/E2 ratio on the day of hCG
administration to the different stimulation protocols,
gonadotropins used and pregnancy and delivery rates.
Material and methods
Study participants
Patients undergoing fresh ART were enrolled prospect-
ively to participate in the study between 1.1.2012 and
31.8.13 at the IVF unit in Hillel Yaffe Medical Center.
To reflect the broad range of patients typically encoun-
tered in clinical practice, no inclusion/exclusion criteria
were applied regarding baseline characteristics except
women’s age <42. Institutional review board approval
was obtained and all patients signed an informed con-
sent in order to participate in the study.
Treatment protocol
The treatment protocol, type and doses of gonadotro-
pins were prescribed on a case-by-case basis according
to patient characteristics and clinician preferences and
judgment. The initial dose of gonadotropin was individ-
ualized for each patient according to age, basal FSH
levels, antral follicle count, body mass index (BMI), and
previous response to ovarian stimulation. Dose adjust-
ments were performed according to ovarian response,
which was monitored by vaginal scans and estradiol de-
terminations. Three main protocols were included in the
study: long agonist protocol, short flare protocol and
antagonist protocol. All treatments protocols were con-
ducted as previously described [12–14].
Medication used
Patients underwent controlled ovarian stimulation by
one of four possible methods: recombinant follicle stimu-
lating hormone (rFSH) alone (Gonal-F, Merck-Serono; or
Puregon, MSD); highly purified human menopausalgonadotropin (HPhMG) alone (Menopur, Ferring Pharma-
ceutical); or rFSH combined with HP-hMG.
Hormone level follow-up
Estrogen and P levels were routinely performed during
the study on every follow-up visit, including on the day of
hCG (Ovitrelle Merck-Serono) administration before egg
retrieval. The P/E2 ratio was calculated as [P (ng/mL) *
1000/E2 (pg/mL)] [15, 16].
After oocyte retrieval, in vitro fertilization (IVF) or intra-
cytoplasmic sperm injection (ICSI) was performed. The
quality of all available embryos was evaluated, and up to
two embryos were transferred on day 2 or 3 of develop-
ment. Embryo quality was evaluated on the day of transfer
according to cells number, symmetry, granularity, type,
percentage of fragmentation, presence of multinucleate
blastomers, and degree of compaction as previously de-
scribed [17]. A top-quality embryo was described as an
embryo with 4–5 cells on day 2 or on day 3, >6 cells
equally sized blastomers and < =20 % fragmentation and
no multinucleate cells.
Pregnancy determination
The β-hCG test was performed 14 days after embryo
transfer, and the clinical pregnancy and implantation
rate was confirmed when a gestational sac with fetal
heart beat was visible by ultrasound examination after
7 weeks of pregnancy.
Demographic data, treatment information and results
and pregnancy outcome were recorded and followed
until delivery.
Power analysis was conducted to answer the main
study’s questions pregnancy rate in low vs. high proges-
terone level and P/E2 ratio above and below 0.48. It was
calculated that 70 women in each group were needed to
detect of 80 % probability power of 22 % difference in
live birth rate (20 and 42 %) between different values of
progesterone and P/E2 ratio based on Cetinkaya et al.
[18] who demonstrated a threshold of P/E2 of 0.48 and
progesterone level of 1.5 ng/ml at a significance level
(alpha) of 0.05.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware package version 21 (SPSS Inc., Chicago, IL). We
used Shapiro Wilks test to evaluate the distribution of
the quantitative parameters in the data. Comparisons be-
tween groups were analyzed using Student’s t test or
Mann–Whitney U test Anova and Kruskal Wallis when
appropriate. Proportions were compared using Chi
Square test or Fisher exact test. P value of less than 0.05
was considered significant. We used a multivariate logis-
tic regression analysis model to rule out any other con-
founders that can influence the clinical results. A
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performed to determine the most efficient cut-off values
for the P/E2 ratio to discriminate between successful and
unsuccessful IVF/ICSI-ET outcomes. The highest value of
the area under the curve (AUC) was determined.
Results
One hundred thirty nine patients were enrolled in the
study. The main characteristics of the group including the
cause of infertility and treatment protocols are presented in
Table 1.
Comparing the 3 different protocols we could not find
any difference in the P level on hCG stimulation day,
however, estradiol and P/E2 ratio were significantly
lower in the long agonist protocol compare with antag-
onist protocol 1757.7 ± 923.2 vs. 1342.9 ± 1223; P = 0.003Table 1 The influence of 3 different protocols on treatment’s param
Long-Ago (N = 55) S
Age 30.87 ± 4.94 3
Cause of Infertility
Mechanical 3 (5.5 %) 4
PCO 4 (7.3 %) 0
Male 26 (47.3 %) 6
Combined 4 (7.3 %) 5
Unexplained 10 (18.2 %) 6
low ovarian reserve 1 (1.8 %) 2
endometriosis 7 (12.7 %) 0
Other 0 2
E2 (pmol/dl) 1757.7 ± 923.2 1
P (ng/mL) 0.6787 ± 0.3169 0
P/E2 ratio 0.48 ± 0.31 0
Endometrial thickness (mm) 10.8 ± 2.3 8
Number of M2 oocytes 8.4 ± 4.5 5
Number of 2PN 5.8 ± 3.1 3
Fertilization rate 69.4 ± 22.7 7
Cleavage rate 97.51 ± 10.13 1
Number of Embryos transfer 2.05 ± 0.48 2
Treatment outcome
Chemical pregnancy (%) 22 (40 %) 6
Clinical pregnancy (%) 19 (34.5 %) 6
Life birth rate (%) 17 (31 %) 4
TOP Quality embryos (%) 42 (76 %) 2
Values are mean ± SD, n, or n/total (%). * Statistical differences between Long vs. A
differences between Antagonist vs. Shortand 0.48 ± 0.31 vs. 0.83 ± 0.87; P = 0.038). Concomitantly,
the endometrium was significantly thicker in the long
agonist group compare with short and antagonist.
On the other hand, significantly more TOP quality
embryos were achieved in the antagonist group
(Table 1).
Comparing the IVF treatment outcome in regards the
gonadotropins used we could not demonstrate any sig-
nificant difference between the r-FSH and HP (hMG)
used in the different protocols of treatment beside em-
bryo’s quality (Table 2).
According to ROC analysis, the P/E2 ratio which can
predict live birth rate was found to be 0.45, AUC =
0.632, p = 0.006 and 95 % Confidence Interval 0.525–
0.738 with sensitivity of 65.7 %; specificity of 62.7 %; and
overall accuracy of 64 % (Fig. 1).eters
hort-Ago (N = 25) Antagonist (N = 59) p
7.00 ± 5.40 32.44 ± 5.50 #0.0001
@0.002
(16.0 %) 8 (13.8 %)
4 (6.9 %)
(24 %) 20 (34.5 %)
(20 %) 6 (10.3 %)
(24 %) 13 (22.4 %)
(8 %) 2 (3.4 %)
3 (5.2 %)
(8 %) 2 (3.4 %)
498 ± 763 1342.9 ± 1223 *0.003
.7424 ± 0.3619 0.6925 ± 0.3336 0.66
.63 ± 0.54 0.83 ± 0.87 *0.038
.7 ± 2.1 9.5 ± 2.2 *0.031
#0.003
.0 ± 3.0 5.9 ± 4.9 *0.003
#0.007
.7 ± 2.2 4.5 ± 3.4 *0.049
#0.03
7.6 ± 20.05 80.7 ± 18.9 *0.025
00 ± 0 98.51 ± 6.3 0.23
.2 ± 0.77 1.88 ± 0.53 0.064
(24 %) 22 (37 %) 0.37
(24 %) 19 (32 %) 0.64
(16 %) 14 (24 %) 0.34
2 (88 %) 56 (95 %) *0.006
ntagonist # Statistical differences between Long vs. Short @ Statistical
Table 2 Comparable results in different gonadotropins used for stimulation
r-FSH (N = 77) hMG (N = 45) Combined Gonadotropins (N = 17) p
E2 (pmol/dl) 1467.2 ± 886.2 1461.6 ± 823.4 2036.0 ± 1892.6 0.45
P (ng/mL) 0.71 ± 0.34 0.63 ± 0.32 0.77 ± 0.28 0.28
P/E2 ratio 0.73 ± 0.79 0.54 ± 0.42 0.59 ± 0.42 0.33
Endometrial thickness (mm) 9.9 ± 2.3 9.6 ± 2.5 10.2 ± 2.2 0.68
Number of M2 oocytes 7.2 ± 4.4 5.4 ± 3.4 8.9 ± 6.8 0.05
Number of 2PN 5.2 ± 3.2 3.9 ± 2.6 5.8 ± 4.5 0.057
Fertilization rate 77.04 ± 20.2 75.02 ± 22.08 70.7 ± 23.8 0.63
Cleavage rate 98.4 ± 5.4 99.26 ± 4.9 95.7 ± 13.31 0.27
Number of Embryos transfer 1.9 ± 0.5 2.1 ± 0.65 2.1 ± 0.64 0.08
Treatment outcome
Chemical pregnancy (%) 32 (42 %) 12 (27 %) 6 (35 %) 0.25
Clinical pregnancy rate (%) 27 (35 %) 11 (24 %) 6 (35 %) 0.45
Live birth rate (%) 21 (27 %) 9 (20 %) 5 (29 %) 0.61
Quality (1 or 1 + 2) 70 (91 %) 38 (84 %) 12 (71 %) *0.038 1 vs. 3
Values are mean ± SD, n, or n/total (%). *statistical significant between r-FSH vs. Combined Gonadotropins
Fig. 1 ROC curve for P/E2 ratio to predict live birth rate
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Table 4 Comparison between delivered and non-delivered
group
No live born Life born p
n = 104 n = 35
Age 33.0 ± 5.9 31.4 ± 4.8 P = 0.15
E2 (pmol/dl) 1545.26 ± 1128.4 1504.3 ± 776.49 P = 0.64
P (ng/mL) 0.73 ± 0.34 0.57 ± 0.26 P= 0.016
P/E2 ratio 0.72 ± 0.73 0.47 ± 0.33 P= 0.020
Endometrial thickness (mm) 9.86 ± 2.43 9.96 ± 2.08 P = 0.80
Number of M2 oocytes 6.66 ± 4.62 7.34 ± 4.64 P = 0.39
Number of 2PN 4.65 ± 3.24 5.5 ± 3.4 P = 0.17
Fertilization rate 74.28 ± 22.1 79.6 ± 17.9 P = 0.28
Cleavage rate 99.1 ± 8.5 99.2 ± 3.84 P = 0.49
Number of Embryos
transfer
2.01 ± 0.58 2.00 ± 0.54 P = 0.76
Protocol
Long 38 (69 %) 17 (31 %)
Short 21 (84 %) 4 (16 %) P = 0.34
Antagonist 45 (76.3 %) 14 (23.7 %)
Total gonadotropin
dose median (range)
1500 (130–4000) 1300 (750–3000) P = 0.012
Values are mean ± SD, n, or n/total (%)
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fertilization rate and cleavage rate were comparable,
endometrial thickness, estradiol level on day of hCG,
number of M2 oocytes collected, clinical pregnancy rate
and most importantly live birth rate were significantly
higher when P/E2 ratio was lower than 0.45 group
(Table 3).
In Table 4, comparing the live birth to no deliveries
cycles we could show that the only difference was found
to be in the P and P/E2 ratio. However in both groups
the progesterone level was in normal range.
We conducted a univariate analysis in order to predict
a live birth rate. Taking into consideration P/E2 ratio,
endometrial thickness, number of MII oocytes retrieved,
type of gonadotrophins used, treatment protocol, total
dosage of gonadotrophins and number of 2PN achieved,
we found that the total dosage of gonadotrophins and
progesterone level on hCG day were significantly corre-
lated with good pregnancy outcome.
Multivariate Logistic regression model was con-
ducted on the basis of the univariate analysis. We in-
cluded parameters that reduce multi-collinearity, such
as age, endometrial thickness, number of MII oocytes
retrieved and number of 2PN, P/E2 ratio and P/E2
ratio <0.45. We found that the P/E2 ratio <0.45 increased
the chance for live birth with odds ratio of 2.8, p = 0.021,
95 % CI = 1.18–7.07.
Discussion
In this study we evaluated prospectively the association
between treatment protocol, gonadotropins used and the
level of progesterone and P/E2 ratio on day of hCG ad-
ministration for ovulation and their impact on treatment
outcome and pregnancy and delivery rate. ROC analysisTable 3 Measurements for ratio p/E2 ≤0.45
P/E2 ≤0.45 P/E2 >0.45 p
(n = 63) (N = 76)
E2 (pmol/dl) 2032.5 ± 1182.3 1122.5 ± 697.7 P < 0.001
P (ng/mL) 0.5492 ± 0.2379 0.8177 ± o.3483 P < 0.001
Endometrial thickness (mm) 10.3 ± 2.1 9.6 ± 2.5 P = 0.037
Number of M2 oocytes 8.62 ± 5.04 5.35 ± 3.64 P < 0.001
Number of 2PN 5.98 ± 3.49 3.95 ± 2.82 P < 0.001
Fertilization rate 72.6 ± 21.9 78.2 ± 20.38 P = 0.15
Cleavage rate 98.7 ± 4.23 98.1 ± 9.6 P = 0.60
Number of Embryos transfer 2.11 ± 0.48 1.92 ± 0.63 P = 0.033
Treatment outcome
Chemical pregnancy 27 (42.9 %) 23 (30.3 %) P = 0.16
Clinical pregnancy 25 (39.7 %) 19 (25 %) P = 0.07
Live birth rate 23 (36.5 %) 12 (15.8 %) P = 0.006
TOP quality embryos 56 (88 %) 64 (84 %) P = 0.47
Values are mean ± SD, n, or n/total (%)established a cutoff value predicting a threshold which
distinguish between live birth and non-live birth cycles.
We demonstrated that a P/E2 ratio with a cutoff <0.45
was predictive for live birth with total accuracy of 64 %.
In Table 4, comparing the live birth to no deliveries cycles
we could show that the only difference was found to be in
the P and P/E2 ratio, however in both groups the proges-
terone level was in normal range, however significantly
lower in the group of live birth. Elgindy et al. suggested a
cutoff of 0.55 to predict clinical pregnancy in agonist
cycles [16]. Others suggested cut-offs of P/E2 <0.48 to
achieve higher pregnancy and deliveries rates, which is
relatively similar to our result, however they analyzed an-
tagonist cycles only [18]. As far as we know this is the only
study that analyze prospectively different protocols and
determined a general cutoff regardless the treatment
protocol treated.
We found that neither the treatment protocol nor the
gonadotropins used had influence on the pregnancy out-
come. The Progesterone and Progesterone/Estradiol ra-
tio were statistically lower in the long agonist protocol.
However, there was no impact on embryo quality in the
antagonist protocol although P/E2 was significantly
higher. This finding is in agreement with previous stud-
ies which demonstrated that high P/E2 ratio has no
effect on oocytes and embryo’s quality [19, 20].
The association between hormone levels and preg-
nancy results in IVF-ICSI cycles are still investigated as
the main focus of the clinical aspect of pregnancy
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steps to achieve live birth is the window of implantation.
A current view is that the optimal synchronization be-
tween decidualization, receptivity and embryo’s invasion
are reflected in that particular narrow phase. In IVF-ET
cycles, we occasionally cause supra-physiological estro-
gen and progesterone levels, which are source of varia-
tions and alterations for oocytes and embryo quality,
endometrial thickness and receptivity, and therefore, im-
pairs pregnancy and delivery rates [21–23].
Contrary to the above said, in the study of Requena
et al., analyzed retrospectively 2850 cycles of high re-
sponders’ women, they aimed to determine the influence
of high progesterone levels on clinical outcomes in the
context of high ovarian response. Interestingly, contra-
dicting other studies mentioned above, including our
study, they demonstrated that increased progesterone
levels was correlated with high estradiol levels and did
not have any detrimental effect on cycle outcome [24].
Bourgain et al. describe different luteal proliferative
changes comparing stimulated cycles and natural cycles.
In the stimulated cycles unfavorable effect was demon-
strated during the early luteal phase and they were cor-
rected during the late luteal phase [25]. In agreement,
Elgindy et al. in their study they revealed that endometrial
receptivity could not be the only mechanism to alter im-
plantation. They describe different implantation rate be-
tween cleavage stage embryo transfer and blastocysts
transfer. In this study they showed lower implantation rate
on day 3 transfer which was completely recovered when
embryos were transferred as blastocysts [26]. Probably the
adverse effect of P/E2 in stimulated cycles were corrected
waiting longer for day 5 transfer and by that overcoming
the miss match of receptivity.
In our study we evaluated the correlation of P/E2 with
different protocols and we followed the delivery rate, by
that we created more generalized information, however
this study was not randomized study.
Our conclusion is that P/E2 ratio <0.45 may be a good
prognostic factor for delivery rate in the main 3 protocol
used in IVF-ICSI cycles. Different gonadotropins used
may have no impact on P/E2 ratio and cycle outcome. A
large cohort study may lighten the influence of different
protocols of stimulation on P/E2 ratio and live birth rate.
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